Most Read Articles
Pank Jit Sin, 30 Nov 2018
The use of pertuzumab in the adjuvant setting significantly increases the rate of invasive-disease-free survival (IDFS) of persons with HER2+ early breast cancer (eBC). 

Rapid onset opioids for the optimized treatment of breakthrough cancer pain

24 Jul 2018
Cancer is hard enough as it is – unnecessarily increasing the treatment does not help patients, doctors or the practice of healthcare in general.
At a recent dinner symposium held during the Abstral® Grand Launch at Le Meridien Putrajaya, Dr Michael Überall spoke on the management of breakthrough cancer pain (BTcP) and highlighted the role of sublingual fentanyl ([SLF], Abstral®; A. Menarini Pte Ltd) in the optimization of BTcP in cancer patients.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 30 Nov 2018
The use of pertuzumab in the adjuvant setting significantly increases the rate of invasive-disease-free survival (IDFS) of persons with HER2+ early breast cancer (eBC).